Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 November 2021 | Story Leonie Bolleurs | Photo Supplied
Prof Abdon Atangana was recently elected a fellow of The World Academy of Sciences (TWAS).

Prof Abdon Atangana, Professor of Applied Mathematics in the Institute for Groundwater Studies at the University of the Free State (UFS), was recently elected a fellow of The World Academy of Sciences (TWAS).

He also received the World Academy of Sciences Award for Mathematics (TWAS -Mohammad A. Hamdan, 2020) on 1 November 2021.

TWAS, described as the voice for science in the South, is working towards the advancement of science in developing countries and supports sustainable prosperity through research, education, policy, and diplomacy. 

Outstanding contribution to science

Prof Mohamed HA Hassan, President of TWAS, congratulated Prof Atangana on this prestigious achievement, “Your election as fellow is a clear recognition of your outstanding contribution to science and its promotion in the developing world. We will be honoured to have you among our members.”

Candidates elected as TWAS Fellows are scientists whose contributions to their respective fields of science meet internationally accepted standards of excellence, and they must have distinguished themselves in efforts to promote science in developing countries. 

Prof Atangana is known for his research to develop a new fractional operator, the Atangana-Baleanu operator, which is to model real-world problems. With this operator, he not only describes the rate at which something will change, but also account for disrupting factors that will help to produce better projections.

Among others, his models can advise people drilling for water by predicting how groundwater is flowing in a complex geological formation. Furthermore, his work can also be applied to predict the spread of infectious diseases among people in a settlement, forecasting the number of people who will be infected each day, the number of people who will recover, and the number of people who will die. 

These are only two examples of how his work can be applied to better the lives of people.

Promoting science in the developing world

Besides promoting science in the developing world, Prof Atangana’s work also contributes to the United Nations Sustainable Development Goals – the global goals as set in 2015 that call for ending poverty, protecting the planet, and ensuring that all people enjoy prosperity and peace.

Prof Atangana says the election as fellow is a clear recognition of his outstanding contribution to science and its promotion in the developing world. “My work over the past five years has made a great impact in all fields of science, technology, and engineering.”

To be elected as TWAS fellow in mathematics, made him the second South African researcher to be elected in the field of mathematics (the first person elected was Prof Reddy Batmanathan Dayanand, who was elected in 2003). This also placed him as the sixth African mathematician to be elected as a TWAS fellow.

Very recently, he also ranked number one in the world in mathematics, number 186 in the world in all the fields, and number one in Africa in all the fields, according to the Stanford list of 2% single-year table.

He was also named among the top 1% of scientists on the global Clarivate Web of Science list. Less than 6 200 or 0,1% of the world's researchers were included on this list in 2020, with no more than 10 of the scientists hailing from South Africa. 

Prof Atangana is also editor of more than 20 top-tier journals of applied mathematics and mathematics, and for some of these journals he was the first African to be selected as editor. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept